ストックスクリーナーアプリを入手
198.09
0.77%
1.51
前日終値:
$196.58
開ける：
$199.48
24時間の取引高:
450.78K
Relative Volume:
0.39
時価総額：
$29.25B
収益：
$9.60B
当期純損益:
$1.37B
株価収益率:
21.26
EPS:
9.3182
ネットキャッシュフロー:
$2.32B
1週間 パフォーマンス:
-0.28%
1か月 パフォーマンス:
+2.23%
6か月 パフォーマンス:
+13.39%
1年 パフォーマンス:
+55.93%
1日の値動き範囲:
$194.74
$200.97
1週間の範囲:
$193.19
$201.75
52週間の値動き範囲:
$121.05
$205.97
Biogen Inc Stock (BIIB) Company Profile
Compare BIIB vs LLY, JNJ, ABBV, NVS, MRK
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
198.09 | 29.02B | 9.60B | 1.37B | 2.32B | 9.3182 |
LLY
Lilly Eli Co
|
1,109.22 | 979.64B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
230.88 | 549.78B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
231.64 | 382.49B | 62.82B | 3.60B | 19.98B | 2.0274 |
NVS
Novartis Ag Adr
|
149.05 | 280.64B | 54.66B | 13.58B | 16.05B | 7.0171 |
MRK
Merck Co Inc
|
115.12 | 281.24B | 65.51B | 8.93B | 14.12B | 3.5532 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-22 | アップグレード | UBS | Neutral → Buy |
| 2026-04-20 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2026-04-14 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2026-02-20 | 開始されました | Barclays | Equal Weight |
| 2026-02-09 | 繰り返されました | H.C. Wainwright | Buy |
| 2026-01-07 | 再開されました | UBS | Neutral |
| 2025-12-10 | ダウングレード | HSBC Securities | Hold → Reduce |
| 2025-11-06 | アップグレード | Stifel | Hold → Buy |
| 2025-09-25 | 開始されました | Jefferies | Buy |
| 2025-07-21 | 再開されました | Truist | Hold |
| 2025-04-28 | ダウングレード | HSBC Securities | Buy → Hold |
| 2025-04-04 | ダウングレード | Argus | Buy → Hold |
| 2025-02-11 | 開始されました | Bernstein | Mkt Perform |
| 2025-01-02 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | ダウングレード | Stifel | Buy → Hold |
| 2024-12-10 | 再開されました | BofA Securities | Neutral |
| 2024-12-09 | ダウングレード | Jefferies | Buy → Hold |
| 2024-11-18 | ダウングレード | Needham | Buy → Hold |
| 2024-11-15 | 開始されました | Wolfe Research | Peer Perform |
| 2024-11-14 | 開始されました | Citigroup | Neutral |
| 2024-10-31 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | 再開されました | Raymond James | Mkt Perform |
| 2024-02-14 | 繰り返されました | Needham | Buy |
| 2024-02-14 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | ダウングレード | UBS | Buy → Neutral |
| 2023-12-20 | 再開されました | Cantor Fitzgerald | Overweight |
| 2023-12-07 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | 開始されました | HSBC Securities | Buy |
| 2023-07-27 | 開始されました | Scotiabank | Sector Outperform |
| 2023-07-24 | 繰り返されました | UBS | Buy |
| 2023-05-01 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-04-17 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | アップグレード | Goldman | Neutral → Buy |
| 2022-10-13 | アップグレード | Stifel | Hold → Buy |
| 2022-10-07 | アップグレード | Argus | Hold → Buy |
| 2022-09-28 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | アップグレード | Mizuho | Neutral → Buy |
| 2022-09-28 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | ダウングレード | Stifel | Buy → Hold |
| 2022-03-03 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | 繰り返されました | Barclays | Equal Weight |
| 2022-02-04 | 繰り返されました | BofA Securities | Neutral |
| 2022-02-04 | 繰り返されました | Cowen | Outperform |
| 2022-02-04 | 繰り返されました | Morgan Stanley | Overweight |
| 2022-02-04 | 繰り返されました | Needham | Buy |
| 2022-02-04 | 繰り返されました | Oppenheimer | Outperform |
| 2022-02-04 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | 繰り返されました | Robert W. Baird | Neutral |
| 2022-02-04 | 繰り返されました | Wedbush | Neutral |
| 2022-02-04 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-02-04 | 繰り返されました | Wolfe Research | Peer Perform |
| 2022-01-13 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-01-12 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | 再開されました | Raymond James | Mkt Perform |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-12-06 | 開始されました | Goldman | Neutral |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-09-23 | 開始されました | Needham | Buy |
| 2021-06-18 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | 繰り返されました | Truist | Buy |
| 2021-06-11 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | アップグレード | UBS | Neutral → Buy |
| 2021-06-08 | アップグレード | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | 繰り返されました | Barclays | Equal Weight |
| 2021-06-08 | アップグレード | Citigroup | Sell → Neutral |
| 2021-06-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-06-08 | 繰り返されました | Jefferies | Buy |
| 2021-06-08 | 繰り返されました | Morgan Stanley | Overweight |
| 2021-06-08 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | アップグレード | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | 繰り返されました | Stifel | Buy |
| 2021-06-08 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | アップグレード | BofA Securities | Underperform → Neutral |
| 2021-06-07 | アップグレード | Cowen | Market Perform → Outperform |
| 2021-06-07 | アップグレード | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | ダウングレード | DZ Bank | Buy → Hold |
| 2021-01-29 | アップグレード | Stifel | Hold → Buy |
| 2020-11-10 | アップグレード | DZ Bank | Hold → Buy |
| 2020-11-09 | ダウングレード | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2020-11-09 | ダウングレード | Cowen | Outperform → Market Perform |
| 2020-11-09 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-11-04 | アップグレード | BofA Securities | Underperform → Neutral |
| 2020-11-04 | アップグレード | Jefferies | Hold → Buy |
| 2020-11-04 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-07-27 | アップグレード | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2020-06-22 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | ダウングレード | Citigroup | Neutral → Sell |
| 2020-04-23 | ダウングレード | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | 開始されました | Wolfe Research | Peer Perform |
| 2020-02-27 | 開始されました | Barclays | Overweight |
| 2020-01-27 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | ダウングレード | Robert W. Baird | Neutral → Underperform |
すべてを表示
Biogen Inc (BIIB) 最新ニュース
Cantor Fitzgerald maintains Biogen stock rating on BIIB080 outlook - Investing.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biogen Inc. (BIIB) And Encourages Shareholders to Reach Out - ACCESS Newswire
Biogen faces Italian antitrust probe over rivalry with Sandoz for MS drugs - MSN
Denali to Sell Priority Review Voucher for $195M Cash Boost - TradingView
Biogen acquires RayThera in deal worth up to $1 billion - qz.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Biogen Inc. (BIIB) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Biogen Inc. stock outperforms competitors despite losses on the day - MarketWatch
Biogen Stock$1 billion RayThera deal to expand immunology pipeline - AD HOC NEWS
Biogen adds more immune drugs in $1B buyout of secretive startup RayThera - BioPharma Dive
Biogen To Acquire RayThera For Up To $1 Billion, Expanding Immunology Pipeline - Benzinga
Biogen Enters $1 Billion Agreement to Acquire RayThera Inc. - Pharmaceutical Executive
Biogen snags San Diego biotech for $1B as immunology expansion continues - The Business Journals
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc.BIIB - PR Newswire
Biogen to Strengthen Immunology Pipeline With $1B RayThera Buyout - Yahoo Finance
Biogen Advancing Diranersen Alzheimer's Drug Into Phase 3 Shows Confidence, Morgan Stanley Says - marketscreener.com
Biogen Agrees to Acquire RayThera for Up to $1B - Contract Pharma
Needham reiterates Buy on Biogen stock after RayThera acquisition - Investing.com
Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million - GlobeNewswire Inc.
Needham reiterates Buy on Biogen stock after RayThera acquisition By Investing.com - Investing.com Canada
Biogen makes up to $1B immuno play with RayThera takeover - BioSpace
Biogen (BIIB) Expands Immunology Portfolio with $1B RayThera Acquisition - Blockonomi
Biogen to Acquire RayThera in Up to $1 Billion Deal to Expand Immunology Pipeline - marketscreener.com
Morgan Stanley Raises Price Target on Biogen to $224 From $206, Keeps Equalweight Rating - marketscreener.com
Biogen (BIIB) to Acquire RayThera Inc. for Up to $1 Billion - GuruFocus
Biogen to Acquire Biotechnology Firm RayThera for Up to $1 Billion - marketscreener.com
Biogen Inc (BIIB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Biogen to Acquire RayThera for Up to $1 Billion - GuruFocus
Biogen (BIIB) to Acquire RayThera for Up to $1 Billion - GuruFocus
Biogen targets immunology growth with $1 billion RayThera deal - reuters.com
Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Biogen to acquire RayThera for up to $1B, boosting immunology pipeline with new drug candidates. - Pluang
Biogen to acquire RayThera for up to $1 billion By Investing.com - Investing.com Canada
Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc. - Biogen
Biogen to acquire RayThera for $1 billion - marketscreener.com
Biogen Expands Immunology Pipeline With Agreement To Acquire Raythera Inc. - TradingView
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Biogen Expands Immunology Pipeline with $1 Billion RayThera Acquisition to Advance Next-Generation Therapies - bio-itworld.com
Biogen Inc. entered into a definitive agreement to acquire RayThera, Inc. from Foresite Capital Management, LLC, OrbiMed Advisors LLC, TTM Capital and others for $1 billion. - marketscreener.com
Biogen to Report Second Quarter 2026 Financial Results July 29, 2026 - Biogen
Biogen Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Biogen Inc. (BIIB) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Biogen (BIIB) Stock After Breakthrough SMA And Lupus Updates Is A 9.4% Undervaluation Story - simplywall.st
Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman - The National Law Review
2026-06-15 | Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:BIIB | Press Release - Stockhouse
Mizuho Trims Price Target on Biogen to $221 From $236, Keeps Outperform Rating - marketscreener.com
Biogen Inc. (BIIB) Stock Analysis: Navigating a 10% Upside Potential with Strategic Collaborations - DirectorsTalk Interviews
Analysts Are Bullish on Top Healthcare Stocks: Biogen (BIIB), Palvella Therapeutics (PVLA) - The Globe and Mail
Bronstein, Gewirtz & Grossman, LLC Is Investigating Biogen Inc. (BIIB) And Encourages Investors to Connect - ACCESS Newswire
Biogen Inc. Stock (US09062X1037): Analyst Needham Sticks With Buy Rating - AD HOC NEWS
Bronstein, Gewirtz & Grossman, LLC Encourages Biogen Inc. (BIIB) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Biogen Inc (BIIB) 財務データ
収益
当期純利益
現金流量
EPS
0.36%
0.50%
大文字化:
|
ボリューム (24 時間):